Estonia In Vitro Diagnostics Market: By Technology, Cytomegalovirus, Epstein–Barr Virus, Tuberculosis, Sexually Transmitted Diseases, Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus, Covid- 19)), Tissue Diagnostics, Sequencing, Country
Estonia In Vitro Diagnostics (IVD) Market size was valued at US$ x billion in 2023 and is poised to grow at a CAGR of x% from 2024-2030. The Estonia in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19. Hospital Acquired Infections (HAI) represent a major clinical, epidemiologic, and economic problem because they are linked to high morbidity and mortality rates and hospitalization costs. In 2022, hospital-acquired infections accounted for highest market value of 690.4 thousand Euros in molecular diagnostics and are expected to reach 704.9 thousand Euros by 2029.
Tissue diagnostics testing continues to serve as one of the gold standards for cancer diagnosis. The type of cancer, the stage, and the extent to which the disease has infiltrated healthy tissue may all be diagnosed via a biopsy. In 2021, Tissue Diagnostics accounted for a market the value of 1.2 Mn Euro and is expected to reach 2.2 Mn Euro by 2029. Estonia is 17 years into its long-term genome sequencing program. The samples are stored in a repository, the Estonian Genome Centre, based in the University of Tartu. As a part of its National Personalized Medicine program in Estonia, from 2018 they carried out a project to recruit and genotype 100,000 new biobank participants. In Estonia, majority of NIPT samples are analyzed on Illumina device.
In Estonia, high growth areas in infectious diseases are HPV, STDs, HIV, Respiratory Infections, Hospital Acquired infections (HAIs). Tissue diagnostics and sequencing in Estonia IVD market also accounted for the high market value. The prevalence of various diseases and investment in healthcare infrastructure are driving market growth. Human papillomavirus (HPV) is a prevalent sexually transmitted infection (STI) linked to cervical cancer. The increasing awareness about the importance of HPV vaccination and its effectiveness in preventing cervical cancer has led to a higher demand for screening and diagnostic tests for HPV in Estonia. The incidence of sexually transmitted diseases (STDs) has been on the rise globally, including in Estonia. Factors such as changing sexual behaviors, inadequate prevention measures, and increased testing and awareness programs have contributed to the higher detection and diagnosis rates of STDs, driving the growth of the Estonia IVD market. Estonia's healthcare infrastructure, particularly in rural areas, may be limited compared to urban centers. The availability and accessibility of advanced diagnostic tools and technologies may be restricted, hindering the estonia IVD market growth. Financial constraints within the healthcare system can limit investment in advanced diagnostic technologies.
|
Report Benchmarks |
Details |
|
By Technology |
|
|
By Technology |
|
|
By Technology |
|
Download Free Sample Report
QIAGEN, Bio-Rad Laboratories, Roche Diagnostics, Thermofisher Scientific, Cepheid, Inc., Abbott, Inc., Seegene, Inc., Illumina, Inc., Dako, Merck, Leica and Abbott.
Hospital-acquired infection is accounted for 690.4 thousand Euros in 2021 and expected to reach 704.9 thousand Euros by 2029. HIV is the second highest disease accounting for 411,4 thousand Euros and is expected to reach 440.1 thousand Euro by 2029
Molecular diagnostics technology is expected to drive the market growth as it is required for various diseases. Tissue Diagnostics accounted for the 2nd highest market value of expected to reach 2,223,85 Euro by 2029.
| 1.Executive Summary |
| 2.Estonia In Vitro Diagnostics Market Introduction |
| 2.1.Estonia In Vitro Diagnostics Market - Taxonomy |
| 2.2.Estonia In Vitro Diagnostics Market - Definitions |
| 2.2.1.Technology |
| 3.Estonia In Vitro Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Estonia In Vitro Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Estonia In Vitro Diagnostics Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Molecular Diagnostics |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Tissue Diagnostics |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sequencing |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Competition Landscape |
| 6.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 6.2.1.QIAGEN |
| 6.2.2.Bio-Rad Laboratories |
| 6.2.3.Roche Diagnostics |
| 6.2.4.Thermofisher Scientific |
| 6.2.5.Cepheid, Inc. |
| 6.2.6.Abbott, Inc. |
| 6.2.7.Illumina, Inc. |
| 6.2.8.Twist Bioscience |
| 6.2.9.Dako |
| 6.2.10.Leica |
| 6.2.6.Abbott |
| 6.2.12.Merck |
| 7. Research Methodology |
| 8. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
